Clinical data | |
---|---|
Pronunciation | /ˌɛntəkəˈpoʊn/ or /ɛnˈtækəpoʊn/ |
Trade names | Comtan, Comtess, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601236 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | COMT inhibitors[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35% |
Protein binding | 98% (binds to serum albumin) |
Metabolism | Liver |
Elimination half-life | 0.4–0.7 hours |
Excretion | Feces (90%), urine (10%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C14H15N3O5 |
Molar mass | 305.290 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Entacapone, sold under the brand name Comtan among others, is a medication used to treat Parkinson's disease.[1] It is used to prevent the wearing off of levodopa/carbidopa before the next dose is due.[1] It is taken by mouth.[3]
Common side effects include uncontrollable movements, nausea, and change in urine color.[2] Other side effects may include abdominal pain, urge to gamble, falling asleep, prostate cancer, low blood pressure with standing, and hallucinations.[1] It works by blocking the enzyme that breaks down levodopa, catechol-O-methyltransferase (COMT).[2]
Entacapone was approved for medical use in Europe in 1998 and the United States in 1999.[1][2] It is available as a generic medication.[3] In the United Kingdom 100 tablets of 200 mg costs the NHS about £16 as of 2021.[3] This amount in the United States costs about 40 USD.[4]
References edit
- ^ a b c d e f "Entacapone Monograph for Professionals". Drugs.com. Archived from the original on 8 May 2021. Retrieved 15 December 2021.
- ^ a b c d "Comtess". Archived from the original on 12 November 2020. Retrieved 15 December 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 433. ISBN 978-0857114105.
- ^ "Entacapone Prices and Entacapone Coupons - GoodRx". GoodRx. Retrieved 15 December 2021.